Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on agenetically engineered platform based on Listeria monocytogenes (aka Lm).[1] The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.[2]
The Lm-based platform on which the company's products were based involves the use of an attenuated Lm, which secretes an antigen/adjuvant fusion protein and stimulates a patient's immune system (specifically their T cells) to mount an immune response to the secreted antigen. If the antigen is specifically found on cancerous cells, the result is an immune response targeting and eliminating the cancer.[1] Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.[1]
The company had over fifteen constructs in various stages of development, both directly and through strategic collaborations with centers, such as the